<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01173614</url>
  </required_header>
  <id_info>
    <org_study_id>ECR-CCRS-2010-01</org_study_id>
    <nct_id>NCT01173614</nct_id>
  </id_info>
  <brief_title>Project Gullstrand - European Project for the Determination of Average Biometric Values of Human Eyes</brief_title>
  <acronym>Gullstrand</acronym>
  <official_title>Project Gullstrand - European Project for the Determination of Average Biometric Values of Human Eyes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Vision Institute Clinical Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Vision Institute Clinical Research Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the average values of human ocular biometry and to
      correlate these values with visual function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>to obtain a predetermined number of valid ocular biometry measurements per participating site</measure>
    <time_frame>19 months</time_frame>
    <description>The test that will be performed are the eye dominance, uncorrected and corrected distance visual acuity (UDVA and CDVA), (accommodation, ocular refraction (automatic refraction), spectacle refraction, axial length (optical, ultrasound), anterior segment biometry (anterior chamber depth), corneal topography (keratometry), contrast sensitivity (Pelli-Robson/ Sine Wave Contrast Test (SWCT), pupil size (gauge)), intraocular pressure, the VFQ-25 questionnaire and some demographic data (age, gender, ethnicity, eye color, highest education).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To obtain a predetermined number of valid visual function measurements per participating site</measure>
    <time_frame>19 months</time_frame>
    <description>The tests that will be performed are the eye dominance, accommodation, uncorrected and spectacle corrected visual acuity (UCVA and SCVA), ocular refraction (automatic refraction), spectacle refraction, axial length (optical, ultrasound), anterior segment biometry (anterior chamber depth), corneal topography (keratometry), contrast sensitivity (Pelli-Robson/ Sine Wave Contrast Test (SWCT)), intraocular pressure, the VFQ-25 questionnaire and some demographic data (age, gender, ethnicity, eye color, highest education).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Provide a reference database for research purposes</measure>
    <time_frame>19 Months</time_frame>
    <description>Protocol foresees in inclusion optional tests:straylight measurement (using Oculus C-Quant,pupillometry,distance-corrected intermediate and near visual acuity(DCIVA and DCNVA,crystalline lens thickness,aberrometry,ORA measurements (IOPcc,IOPG,CRF,CH parameters.These tests may be added by the individual sites depending of the availability of equipment.A number of secondary parameters can also be derived from primary parameters using calculations (e.g.crystalline lens power, estimated aniseikonia,etc) or by analysis of the raw data of computer based tests.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1646</enrollment>
  <condition>Normal Subjects, Ametropia</condition>
  <arm_group>
    <arm_group_label>Normal subjects</arm_group_label>
    <description>Subjects with two normal eyes.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Normal subjects
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Two normal eyes

          -  Ametropia between -10D and +10D.

        Exclusion Criteria:

          -  One pathological eye

          -  Prior ocular surgery

          -  Amblyopia, refraction larger than ±10D

          -  Corneal or retinal pathologies

          -  Systemic diseases (e.g. diabetes, multiple sclerosis, …)

          -  More than 5 months pregnant at the moment of testing

          -  Recent wear of hard contact lenses

          -  Epilepsy (if C-Quant is used).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jos Rozema, MSc PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept of Ophthalmology, Antwerp University Hospital. Edegem, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie-José Tassignon, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Ophthalmology, Antwerp University Hospital. Edegem, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sotiris Plainis, MSc PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Vision and Optics (IVO), University of Crete, School of Health Sciences, Heraklion Crete, Greece 71003</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VISSUM - Instituto Oftalmológico de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2010</study_first_submitted>
  <study_first_submitted_qc>July 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2010</study_first_posted>
  <last_update_submitted>June 14, 2016</last_update_submitted>
  <last_update_submitted_qc>June 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

